We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.51B
AUM Growth
+$203K
Cap. Flow
-$184M
Cap. Flow %
-4.08%
Top 10 Hldgs %
82.68%
Holding
115
New
24
Increased
20
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$15.8M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
3
MET icon
MetLife
MET
+$10.7M
4
TSRO
TESARO, Inc.
TSRO
+$8.14M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.5M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$41.4M
2
BLUE
bluebird bio
BLUE
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.9M
4
CELG
Celgene Corp
CELG
+$12M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.24M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.81%
2 Healthcare 28.52%
3 Consumer Discretionary 10.77%
4 Financials 0.73%
5 Industrials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
101
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-650,000
Closed -$3.23M
FXI icon
102
CALL
iShares China Large-Cap ETF
FXI
$4.32B
– –
-1,000,000
Closed -$34.7M
INCY icon
103
CALL
Incyte
INCY
$25.4B
– –
-100,000
Closed -$10M
IONS icon
104
CALL
Ionis Pharmaceuticals
IONS
$8.93B
– –
-200,000
Closed -$9.57M
JD icon
105
CALL
JD.com
JD
$43.5B
– –
-250,000
Closed -$6.36M
LLY icon
106
CALL
Eli Lilly
LLY
$1.08T
– –
-200,000
Closed -$14.7M
MS icon
107
CALL
Morgan Stanley
MS
$319B
– –
-150,000
Closed -$6.34M
NBIX icon
108
CALL
Neurocrine Biosciences
NBIX
$18.2B
– –
-100,000
Closed -$3.87M
PFE icon
109
CALL
Pfizer
PFE
$143B
– –
-527,000
Closed -$16.2M
WMT icon
110
CALL
Walmart Inc
WMT
$909B
– –
-1,500,000
Closed -$34.6M
CLVS
111
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-50,000
Closed -$2.22M
ALXN
112
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-350,000
Closed -$42.8M
CEMP
113
DELISTED
Cempra, Inc.
CEMP
– –
-200,000
Closed -$560K
CLCD
114
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-5,575
Closed -$203K
CELG
115
DELISTED
Celgene Corp
CELG
– –
-100,000
Closed -$12M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2017 Portfolio in Review

As of Q1 2017, Artal Group held 115 positions worth $4.51B, up 0% from $4.5B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $184M in Q1 2017, closing 20 positions and reducing 23 holdings. Its most notable exit was Celgene Corp, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 45% of assets, down from 47% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Ionis Pharmaceuticals worth $10.1M.

  • Artal Group's largest Q1 2017 buy was Ionis Pharmaceuticals: 250,000 shares worth $10.1M.
  • Artal Group added most to Acceleron Pharma in Q1 2017, an estimated $15.8M increase.
  • Artal Group's biggest Q1 2017 reduction was Incyte, cutting an estimated $41.4M.
  • Artal Group fully exited Celgene Corp in Q1 2017, selling an estimated $12M.
  • Artal Group's ten largest holdings make up 83% of its $4.51B portfolio in Q1 2017.
  • Artal Group opened 24 new positions and closed 20 in Q1 2017.
  • Artal Group's portfolio value rose 0% quarter-over-quarter to $4.51B.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.